Standard BioTools Inc. Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)
Standard BioTools Inc. (LAB) reported Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) of $632.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2025-03-11
- Standard BioTools Inc. fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2024 was $632.00K.
- Standard BioTools Inc. fair value, liability, recurring basis, still held, unrealized gain (loss) for fiscal 2023 was $0.00.
| Period end | Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|
| 2024-12-31 | $632.00K 10-K · filed 2025-03-11 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |